Before the visit Considering a thymalfasin offer

StartSource notes

Follow the statement back to its source.

Use these links to check the answers in this guide. Each note says what the record can tell you, and what it cannot tell you.

What was approved in the United States?

As of September 28, 2026, the FDA review record and approval searches found no U.S. approval for thymosin alpha-1.

What do the pharmacy ingredient records say?

The FDA ingredient page, marked April 22, 2026, still lists concerns about the ingredient. The request to allow its use was taken back by whoever submitted it.

The panel’s meeting record describes its December 4, 2024 advice against listing two forms of the same ingredient. Their names in that record are thymosin alpha-1 (free base) and thymosin alpha-1 acetate.

What did the hospital studies show?

The TESTS paper in BMJ, published in 2025, found no clear reduction in deaths within 28 days in adults with sepsis.

Sepsis is a life-threatening response to an infection. The study does not answer whether healthy adults benefit.

Where can I check a care offer?

Rules about getting care were checked September 26, 2026. The licence-search tools were checked September 17, 2026.

Checking a licence cannot establish care quality or show whether the product’s rules allow that medicine to be supplied.

Keep the date with the answer.

If an offer says the rules have changed since these checks, ask to see the new rule or approval record. Compare its date with the dates on this page.